Cambridge Crystallographic Data Centre and InhibOx Create new Powerhouse in Drug Discovery and Development Services
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
InhibOx Ltd (Oxford, UK) and the Cambridge Crystallographic Data Centre (Cambridge, UK) announce that they have joined forces to create a drug discovery service offering. Users of the new service will benefit from the shared depth of expertise that includes extensive commercial drug discovery experience and from the proprietary technologies developed by the Oxford and Cambridge bodies.
The combined service offers pharmaceutical, biotech and governmental research organizations access to new capabilities to accelerate drug discovery and improve productivity. It includes full-spectrum computer-aided drug discovery (CADD) from receptor site modeling, through lead identification, lead optimization and ADME property prediction to formulation modeling.
The new service offers life science companies a step-change in the quality and effectiveness of CADD services through the use of leading proprietary technologies and databases, applied by scientists with deep commercial drug discovery experience.
The two bodies have set up a joint team to commercialize and support the new service and will share operating expenses and revenues. Sales and service operations for the new, combined service are based out of Oxford and Cambridge, UK, and Princeton, NJ.
The two organizations will also collaborate on the development of new approaches to bring scientific breakthroughs and productivity benefits to all aspects of computer-aided drug discovery, delivering the greatest possible rigor to the process.
The driving force behind the alliance came from the CCDC's global and evolving user community. "We have been asked more and more frequently by our users whether we can bring to bear our in-house drug discovery experience to address their research challenges," said Dr Colin Groom, Executive Director at CCDC. "The alliance with InhibOx gives us the breadth of technology and a focused team to meet this demand. We at CCDC are keen to do more work with our users across the research community and this exciting development will take us forward rapidly to be able to achieve this."
"The timing could not be better," explained Paul Davie, CEO of InhibOx. "The drive to outsourcing by major pharmaceutical enterprises, and the resulting emergence of a new wave of biotechs and CRO's, has created a sudden need for high quality computer-aided drug discovery services. CADD cannot be delivered effectively by companies with just point solutions or a few off-the-shelf tools. This partnership gives the industry what it really needs - a full spectrum, best of breed service offering, delivered by a team with real world drug design and development experience in companies such as Pfizer, GSK, UCB, ICI, Dow and several of the world's top academic institutions."
The InhibOx-CCDC team is offering a flexible scale of services, ranging from focused problem solution provision through to complete drug discovery project assignments.
The combined service offers pharmaceutical, biotech and governmental research organizations access to new capabilities to accelerate drug discovery and improve productivity. It includes full-spectrum computer-aided drug discovery (CADD) from receptor site modeling, through lead identification, lead optimization and ADME property prediction to formulation modeling.
The new service offers life science companies a step-change in the quality and effectiveness of CADD services through the use of leading proprietary technologies and databases, applied by scientists with deep commercial drug discovery experience.
The two bodies have set up a joint team to commercialize and support the new service and will share operating expenses and revenues. Sales and service operations for the new, combined service are based out of Oxford and Cambridge, UK, and Princeton, NJ.
The two organizations will also collaborate on the development of new approaches to bring scientific breakthroughs and productivity benefits to all aspects of computer-aided drug discovery, delivering the greatest possible rigor to the process.
The driving force behind the alliance came from the CCDC's global and evolving user community. "We have been asked more and more frequently by our users whether we can bring to bear our in-house drug discovery experience to address their research challenges," said Dr Colin Groom, Executive Director at CCDC. "The alliance with InhibOx gives us the breadth of technology and a focused team to meet this demand. We at CCDC are keen to do more work with our users across the research community and this exciting development will take us forward rapidly to be able to achieve this."
"The timing could not be better," explained Paul Davie, CEO of InhibOx. "The drive to outsourcing by major pharmaceutical enterprises, and the resulting emergence of a new wave of biotechs and CRO's, has created a sudden need for high quality computer-aided drug discovery services. CADD cannot be delivered effectively by companies with just point solutions or a few off-the-shelf tools. This partnership gives the industry what it really needs - a full spectrum, best of breed service offering, delivered by a team with real world drug design and development experience in companies such as Pfizer, GSK, UCB, ICI, Dow and several of the world's top academic institutions."
The InhibOx-CCDC team is offering a flexible scale of services, ranging from focused problem solution provision through to complete drug discovery project assignments.
